Search results for "potency"

showing 10 items of 122 documents

Evaluating the antifibrotic potency of galunisertib in a human ex vivo model of liver fibrosis

2017

Background and Purpose Liver fibrosis is a major cause of liver-related mortality and, so far, no effective antifibrotic drug is available. Galunisertib, a TGF-β receptor type I kinase inhibitor, is a potential candidate for the treatment of liver fibrosis. Here, we evaluated the potency of galunisertib in a human ex vivo model of liver fibrosis. Experimental Approach Antifibrotic potency and associated mechanisms were studied ex vivo, using both healthy and cirrhotic human precision-cut liver slices. Fibrosis-related parameters, both transcriptional and translational level, were assessed after treatment with galunisertib. Key Results Galunisertib showed a prominent antifibrotic potency. Ph…

0301 basic medicinePharmacologymedicine.medical_specialtyPharmacologyBiologyExtracellular matrix03 medical and health sciences030104 developmental biology0302 clinical medicineEndocrinologyMechanism of action030220 oncology & carcinogenesisInternal medicinemedicineHepatic stellate cellGalunisertibPotencymedicine.symptomSignal transductionReceptorEx vivoBritish Journal of Pharmacology
researchProduct

Mitochondrial Dynamics: In Cell Reprogramming as It Is in Cancer

2017

Somatic cells can be reprogrammed into a pluripotent cellular state similar to that of embryonic stem cells. Given the significant physiological differences between the somatic and pluripotent cells, cell reprogramming is associated with a profound reorganization of the somatic phenotype at all levels. The remodeling of mitochondrial morphology is one of these dramatic changes that somatic cells have to undertake during cell reprogramming. Somatic cells transform their tubular and interconnected mitochondrial network to the fragmented and isolated organelles found in pluripotent stem cells early during cell reprogramming. Accordingly, mitochondrial fission, the process whereby the mitochond…

0301 basic medicinelcsh:Internal medicineInduced stem cellsSomatic cellReview ArticleCell BiologyBiologyEmbryonic stem cellCell biology03 medical and health sciences030104 developmental biologymitochondrial fusionMitochondrial fissionlcsh:RC31-1245Induced pluripotent stem cellMolecular BiologyCell potencyReprogrammingStem Cells International
researchProduct

NO donors. Part 16: investigations on structure-activity relationships of organic mononitrates reveal 2-nitrooxyethylammoniumnitrate as a high potent…

2007

The vasoactive properties of 14 organic mononitrates were investigated in vitro using PGF(2alpha)-precontracted porcine pulmonary arteries. A surprisingly wide range of vasorelaxant potencies was observed (pD(2): 3.36-7.50). Activities showed to be highly sensitive to the molecular structure and the substituents at the molecular carrier of the nitrate group. A correlation between lipophilicity and vasorelaxant potency could not be recognized. 2-Nitrooxyethylammoniumnitrate (1) was found to be slightly superior to the high potency trinitrate GTN.

2-nitrooxyethylammoniumnitrateNitratesChemistryStereochemistryVasodilator AgentsOrganic ChemistryClinical BiochemistryPharmaceutical ScienceVasodilationBiochemistryChemical synthesisIn vitroNo donorsQuaternary Ammonium CompoundsStructure-Activity RelationshipDrug DiscoveryLipophilicityMolecular MedicinePotencyStructure–activity relationshipNitric Oxide DonorsMolecular BiologyBioorganicmedicinal chemistry letters
researchProduct

Some results on locally finite groups

2017

En esta tesis se presentan algunos resultados sobre p-nilpotencia y permutabilidad en grupos localmente finitos. Está estructurada en cinco capítulos. El primer capítulo, que tiene carácter introductorio: contiene definiciones y resultados conocidos que serán utilizados en los capítulos sucesivos. Por tratarse de resultados ya conocidos, se introducen con referencias y sin demostraciones. En el capítulo 2 se trata la p-nilpotencia en grupos hiperfinitos, donde p es un primo. Los resultados presentados se encuentran publicados en el siguiente artículo: Ballester-Bolinches, A.; Camp-Mora, S.; Spagnuolo, F., "On p-nilpotency of hyperfinite groups". Monatshefte f¨ur Mathematik, 176, no. 4, 497–…

:MATEMÁTICAS::Álgebra::Grupos generalidades [UNESCO]UNESCO::MATEMÁTICAS::Álgebra::Grupos generalidadesRanks of groupsp-nilpotencyGroup theorySupersoluble groupsLocally finite groups
researchProduct

Anticoagulant Activity of the Enantiomers of Acenocoumarol in Man

1978

For the mono-coumarin derivatives warfarin and phen-procoumon it was shown that in man and rats the S(−) enantiomer is several times more potent as anticoagulant than the R(+) enantiomer. These stereoselective differences in the anticoagulant potency reflect differences in the affinity for the receptor site rather than differences in the pharmacokinetics.

Acenocoumarolmedicine.drug_classChemistryAnticoagulantWarfarinPharmacologyGlucaric AcidPharmacokineticsmedicinePotencyheterocyclic compoundsStereoselectivityEnantiomermedicine.drug
researchProduct

Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users.

2013

UNLABELLED: Cannabis use is associated with an earlier age of onset of psychosis (AOP). However, the reasons for this remain debated. METHODS: We applied a Cox proportional hazards model to 410 first-episode psychosis patients to investigate the association between gender, patterns of cannabis use, and AOP. RESULTS: Patients with a history of cannabis use presented with their first episode of psychosis at a younger age (mean years = 28.2, SD = 8.0; median years = 27.1) than those who never used cannabis (mean years = 31.4, SD = 9.9; median years = 30.0; hazard ratio [HR] = 1.42; 95% CI: 1.16-1.74; P < .001). This association remained significant after controlling for gender (HR = 1.39; 95% …

AdultAffective Disorders PsychoticMaleRiskage of onset cannabis drug use gender high-potency cannabis psychotic disorders survival plotsPsychosisPediatricsmedicine.medical_specialtySex FactorsDelta-9-tetrahydrocannabinolSettore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat.medicineHumansAge of OnsetPsychiatrySettore MED/25 - PsichiatriaCannabisFirst episodebiologyProportional hazards modelHazard ratioRegular Articlemedicine.diseasebiology.organism_classificationPsychiatry and Mental healthPsychotic DisordersSchizophreniaFemaleCannabisAge of onsetPsychologySchizophrenia bulletin
researchProduct

Identification and expansion of human osteosarcoma-cancer-stem cells by long-term 3-aminobenzamide treatment

2009

A novel cancer stem-like cell line (3AB-OS), expressing a number of pluripotent stem cell markers, was irreversibly selected from human osteosarcoma MG-63 cells by long-term treatment (100 days) with 3-aminobenzamide (3AB). 3AB-OS cells are a heterogeneous and stable cell population composed by three types of fibroblastoid cells, spindle-shaped, polygonal-shaped, and rounded-shaped. With respect to MG-63 cells, 3AB-OS cells are extremely smaller, possess a much greater capacity to form spheres, a stronger self-renewal ability and much higher levels of cell cycle markers which account for G1-S/G2-M phases progression. Differently from MG-63 cells, 3AB-OS cells can be reseeded unlimitedly wit…

AdultHomeobox protein NANOGAdolescentPhysiologyCellular differentiationClinical BiochemistryApoptosisBiologyStem cell markerYoung Adultcancer stemm cells osteosarcoma PARP inhibitorsCancer stem cellCell Line TumorSettore BIO/10 - BiochimicaHumansRhodamine 123Enzyme InhibitorsProgenitor cellChildInduced pluripotent stem cellCell ShapeCell potencyFluorescent DyesOsteosarcomaCell DifferentiationCell BiologyCalcium Channel BlockersDrug Resistance MultipleGene Expression Regulation NeoplasticVerapamilBenzamidesImmunologyNeoplastic Stem CellsCancer researchATP-Binding Cassette TransportersBenzimidazolesStem cellBiomarkersJournal of Cellular Physiology
researchProduct

New levothyroxine formulation meeting 95–105% specification over the whole shelf-life: results from two pharmacokinetic trials

2016

Small levothyroxine (L-T4) dose changes can lead to significant clinical effects. To ensure thyroid hormone levels are safely maintained, authorities are increasingly adopting stricter potency specifications for L-T4, the most stringent of these being 95-105% of the labeled dose over the whole shelf-life. Levothyroxine sodium (Euthyrox, Eutirox, Lévothyrox ) has been reformulated, and two studies performed, to ensure bioequivalence to the currently marketed formulation and dosage form proportionality of the new formulation.The bioequivalence study was an open-label, randomized, single-dose, two-period, two-sequence crossover comparing the highest dosage strengths of the currently marketed a…

AdultMaleChemistry PharmaceuticalLevothyroxine030209 endocrinology & metabolismPharmacologyBioequivalenceShelf lifeDosage form03 medical and health sciences0302 clinical medicinePharmacokineticsHumansMedicinePotencyCross-Over Studiesbusiness.industryGeneral MedicineCrossover studyThyroxineTherapeutic EquivalencyArea Under Curve030220 oncology & carcinogenesisFemalebusinessTabletsmedicine.drugLevothyroxine SodiumCurrent Medical Research and Opinion
researchProduct

Ezetimibe/Simvastatin 10/20 mg versus Rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency

2010

Abstract Objective This post-hoc analysis compared the lipid-altering efficacy of Ezetimibe/Simvastatin 10/20 mg (EZ/Simva) versus Rosuvastatin 10 mg (Rosuva) in patients stratified by statin potency/dose prior to randomization. Methods Patients with elevated low-density lipoprotein cholesterol (LDL-C) despite prior statin treatment (n = 618) were randomized 1:1 to EZ/Simva 10/20 mg or Rosuva 10 mg for 6 weeks. Percent change from baseline in lipids and attainment of lipid targets were assessed within each subgroup (low potency n = 369, high potency n = 249). Consistency of the treatment effect across subgroups was evaluated by testing for treatment-by-subgroup interaction. No multiplicity …

AdultMaleSimvastatinmedicine.medical_specialtySettore MED/09 - Medicina InternaStatinRandomizationAdolescentmedicine.drug_classEndocrinology Diabetes and MetabolismHypercholesterolemiaClinical BiochemistryUrologyPharmacologyYoung AdultEndocrinologyEzetimibemedicineHumansPotencyRosuvastatinRosuvastatin Calciumlcsh:RC620-627AgedBiochemistry medicalAged 80 and overSulfonamidesSimvastatin; Ezetimibe;hypercholesterolemic;ChemistryhypercholesterolemicResearchAnticholesteremic AgentsBiochemistry (medical)nutritional and metabolic diseasesMiddle AgedEzetimibeFluorobenzeneslcsh:Nutritional diseases. Deficiency diseasesRosuvastatin CalciumPyrimidinesTreatment OutcomeSimvastatinAzetidinesFemalelipids (amino acids peptides and proteins)Ezetimibe/simvastatinHydroxymethylglutaryl-CoA Reductase Inhibitorsmedicine.drugLipids in Health and Disease
researchProduct

Roles of participation and feedback in group potency.

2009

The roles of group participation and group performance feedback were examined as antecedents of group potency, i.e., beliefs shared among a work group's members about the general effectiveness of the work group. Also examined were how group participation and the congruence of the feedback received from different sources about performance predicted convergence in members' beliefs about group effectiveness. The sample comprised 61 work groups of professionals involved in Master in Business Administration (MBA) programs (284 participants). Mean group size was 4.6 members ( SD = .58). 65% of participants were male, and 51% were between 30 and 40 years of age. Data were gathered at two measurem…

AdultMaleTeam effectivenessEfficiency OrganizationalFeedbackPotencyHumansLongitudinal StudiesCooperative BehaviorStudentsGeneral PsychologyGroup performanceDecision Making OrganizationalTeachingCommerceOrganizational CultureSelf EfficacyGroup ProcessesResearch DesignModels OrganizationalRegression AnalysisFemalePsychologyWorking groupSocial psychologyClinical psychologyPsychological reports
researchProduct